Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAlaa Sada
About this trial
Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery.
This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.
Eligibility criteria
Qualifiers
Adults aged 18 years and older
Diagnosis of MACS, defined as morning cortisol >1.8 mcg/dL after a 1 mg dexamethasone suppression test
Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2025 American College of Cardiology/American Heart Association [ACC/AHA] criteria, or current use of antihypertensive medication)
BMI ≥27
Disqualifiers
Bilateral adrenal lesions
Adrenal malignancy
Concurrent primary aldosteronism with MACS
Current use of GLP-1 receptor agonists
Trial design
Treatments tested in this trial
- Tirzepatide
- Standard medical treatment
Treatment groups
34 Participants
are divided into 2 treatment groupsSponsors and collaborators
Alaa Sada
Lead sponsor
University of Pittsburgh
Sponsor institution
Source ClinicalTrials.gov